Literature DB >> 21514761

Acute myocardial infarction in a 56-year-old female patient treated with sulfasalazine.

Amin Daoulah1, Awad A R Alqahtani, Sara R Ocheltree, Abdulkarim Alhabib, Ali R Ocheltree.   

Abstract

Drug rash, eosinophilia, and systemic symptoms (DRESS) syndrome represents one pattern of the cutaneous involvement in type IV hypersensitivity reaction to drugs. It is a severe, delayed, idiosyncratic reaction presented as rash with fever, lymphadenopathy, and visceral involvement. There are several reported cases of sulfasalazine-induced DRESS syndrome, but myocardial involvement was rare. High index of suspicion is needed in every patient receiving these drugs for prompt diagnosis and early management. We report a case of a 56-year-old woman treated with sulfasalazine for ankylosing spondylitis for 3 weeks, which was discontinued after development of DRESS syndrome. Despite treating her with high dose of steroid and cyclosporine, her symptoms persisted, and ultimately, she developed toxic myocarditis with a misleading presentation of acute ST-elevated myocardial infarction. The diagnosis was made based on postmortem histopathologic finding.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21514761     DOI: 10.1016/j.ajem.2011.02.018

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  2 in total

1.  Fatal sulfasalazine-induced eosinophilic myocarditis in a patient with periodic fever syndrome.

Authors:  Ivica Jeremic; Nada Vujasinovic-Stupar; Tatjana Terzic; Nemanja Damjanov; Milos Nikolic; Branka Bonaci-Nikolic
Journal:  Med Princ Pract       Date:  2014-12-16       Impact factor: 1.927

Review 2.  "Heart in DRESS": Cardiac Manifestations, Treatment and Outcome of Patients with Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome: A Systematic Review.

Authors:  Milan Radovanovic; Djordje Jevtic; Andrew D Calvin; Marija Petrovic; Margaret Paulson; Libardo Rueda Prada; Lawrence Sprecher; Ivana Savic; Igor Dumic
Journal:  J Clin Med       Date:  2022-01-28       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.